Genetic determinants and epidemiology of cystic fibrosis-related diabetes: results from a British cohort of children and adults

Amanda I Adler, Brian S F Shine, Parinya Chamnan, Charles S Haworth, Diana Bilton, Amanda I Adler, Brian S F Shine, Parinya Chamnan, Charles S Haworth, Diana Bilton

Abstract

Objective: Longer survival of patients with cystic fibrosis has increased the occurrence of cystic fibrosis-related diabetes (CFRD). In this study we documented the incidence of CFRD and evaluated the association between mutations responsible for cystic fibrosis and incident CFRD, while identifying potential risk factors.

Research design and methods: This was a population-based longitudinal study of 50 cystic fibrosis speciality clinics in the U.K. Subjects included 8,029 individuals aged 0-64 years enrolled in the U.K. Cystic Fibrosis Registry during 1996-2005. Of these, 5,196 with data and without diabetes were included in analyses of incidence, and 3,275 with complete data were included in analyses of risk factors. Diabetes was defined by physician diagnosis, oral glucose tolerance testing, or treatment with hypoglycemic drugs.

Results: A total of 526 individuals developed CFRD over 15,010 person-years. The annual incidence was 3.5%. The incidence was higher in female patients and in patients with mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene in classes I and II. In a multivariate model of 377 cases of 3,275 patients, CFTR class (relative risk 1.70 [95% CI 1.16-2.49], class I or II versus others), increasing age, female sex, worse pulmonary function, liver dysfunction, pancreatic insufficiency, and corticosteroid use were independently associated with incident diabetes.

Conclusions: The incidence of CFRD is high in Britain. CFTR class I and II mutations increase the risk of diabetes independent of other risk factors including pancreatic exocrine dysfunction.

Figures

Figure 1
Figure 1
Incidence of CFRD per 100 person-years by age and sex. Vertical bars represent 95% confidence limits; ▪, male patients; □, female patients.
Figure 2
Figure 2
Incidence of CFDR per 100 person-years by class of CFTR mutation. Vertical bars represent 95% confidence limits.

References

    1. Moran A, Doherty L, Wang X, Thomas W: Abnormal glucose metabolism in cystic fibrosis. J Pediatr 133:10–17, 1998
    1. Lanng S, Hansen A, Thorsteinsson B, Nerup J, Koch C: Glucose tolerance in patients with cystic fibrosis: five year prospective study. BMJ 311:655–659, 1995
    1. Adler AI, Gunn E, Haworth C, Bilton D: Characteristics of adults with and without cystic fibrosis-related diabetes. Diabet Med 24:1143–1148, 2007
    1. Marshall B, Butler S, Stoddard M, Moran A, Liou T, Morgan W: Epidemiology of cystic fibrosis-related diabetes. J Pediatr 146:681–687, 2005
    1. Koch C, Rainisio M, Madessani U, Harms HK, Hodson ME, Mastella G, McKenzie SG, Navarro J, Strandvik B: Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol 32:343–350, 2001
    1. Sims EJ, Green M, Mehta A: Decreased lung function in female but not male subjects with established cystic fibrosis-related diabetes. Diabetes Care 28:1581–1587, 2005
    1. Koch C, Cuppens H, Rainisio M, Madessani U, Harms H, Hodson M, Mastella G, Navarro J, Strandvik B, McKenzie S: European Epidemiologic Registry of Cystic Fibrosis (ERCF): comparison of major disease manifestations between patients with different classes of mutations. Pediatr Pulmonol 31:1–12, 2001
    1. Cucinotta D, De Luca F, Scoglio R, Lombardo F, Sferlazzas C, Di Benedetto A, Magazzu G, Raimondo G, Arrigo T: Factors affecting diabetes mellitus onset in cystic fibrosis: evidence from a 10-year follow-up study. Acta Paediatr 88:389–393, 1999
    1. Rosenfeld M, Davis R, FitzSimmons S, Pepe M, Ramsey B: Gender gap in cystic fibrosis mortality. Am J Epidemiol 145:794–803, 1997
    1. Pan H, Cole T: User's Guide to lmsGrowth [article online], 2007. London, Medical Research Council UK. Available from . Accessed 30 April 2008
    1. Hankinson J, Odencrantz J, Fedan K: Spirometric reference values from a sample of the U.S. population. Am J Respir Crit Care Med 159:179–187, 1999
    1. Rowntree RK, Harris A: The phenotypic consequences of CFTR mutations. Ann Intern Med 67:471–485, 2003
    1. McKone EF, Emerson SS, Edwards KL, Aitken ML: Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet 361:1671–1676, 2003
    1. Nousia-Arvanitakis S, Galli-Tsinopoulou A, Karamouzis I: Insulin improves clinical status of patients with cystic-fibrosis-related diabetes mellitus. Acta Paediatr 90:515–519, 2001
    1. Ahmed N, Corey M, Forstner G, Zielenski J, Tsui LC, Ellis L, Tullis E, Durie P: Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas. Gut 52:1159–1164, 2003
    1. Rosenecker J, Eichler I, Kuhn L, Harms H, von der Hardt H: Genetic determination of diabetes mellitus in patients with cystic fibrosis: a multicenter study screening fecal elastase 1 concentrations in 1,021 diabetic patients. J Pediatr 127:441–443, 1995
    1. Hamdi I, Payne SJ, Barton DE, McMahon R, Green M, Shneerson JM, Hales CN: Genotype analysis in cystic fibrosis in relation to the occurrence of diabetes mellitus. Clin Genet 43:186–189, 1993
    1. Dominguez-Garcia A, Quinteiro-Gonzalez S, Pena-Quintana L, Ramos-Macias L, Quintana-Martel M, Saavedra-Santana P: Carbohydrate metabolism changes in cystic fibrosis. J Pediatr Endocrinol Metab 20:621–632, 2007
    1. Preumont V, Hermans MP, Lebecque P, Buysschaert M: Glucose homeostasis and genotype-phenotype interplay in cystic fibrosis patients with CFTR gene ΔF508 mutation. Diabetes Care 30:1187–1192, 2007
    1. Boom A, Lybaert P, Pollet JF, Jacobs P, Jijakli H, Golstein PE, Sener A, Malaisse WJ, Beauwens R: Expression and localization of cystic fibrosis transmembrane conductance regulator in the rat endocrine pancreas. Endocrine 32:197–205, 2007
    1. Stalvey MS, Muller C, Schatz DA, Wasserfall CH, Campbell-Thompson ML, Theriaque DW, Flotte TR, Atkinson MA: Cystic fibrosis transmembrane conductance regulator deficiency exacerbates islet cell dysfunction after β-cell injury. Diabetes 55:1939–1945, 2006
    1. Mulberg AE, Weyler RF, Altschuler SM, Hyde TM: Cystic fibrosis transmembrane conductance regulator expression in human hypothalamus. Neuroreport 9:141–144, 1998
    1. Littlewood JM, Wolfe SP, Conway SP: Diagnosis and treatment of intestinal malabsorption in cystic fibrosis. Pediatr Pulmonol 41:35–49, 2006
    1. Rosenecker J, Hofler R, Steinkamp G, Eichler I, Smaczny C, Ballmann M, Posselt HG, Bargon J, von der Hardt H: Diabetes mellitus in patients with cystic fibrosis: the impact of diabetes mellitus on pulmonary function and clinical outcome. Eur J Med Res 6:345–350, 2001
    1. Milla CE, Billings J, Moran A: Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis. Diabetes Care 28:2141–2144, 2005
    1. Hsia CC, Raskin P: The diabetic lung: relevance of alveolar microangiopathy for the use of inhaled insulin. Am J Med 118:205–211, 2005

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe